HC Wainwright Reaffirms “Buy” Rating for OKYO Pharma (NASDAQ:OKYO)

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $7.00 price objective on the stock.

OKYO Pharma Price Performance

Shares of OKYO stock opened at $1.09 on Monday. The stock’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $1.07. OKYO Pharma has a twelve month low of $0.81 and a twelve month high of $1.90.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.